Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by goldn1on Nov 14, 2019 7:48pm
92 Views
Post# 30353784

RE:RE:RE:RE:RE:Ph2 results

RE:RE:RE:RE:RE:Ph2 results
Claridge:

I certainly hope you are wrong in regards to the 3 month data. One of the biggest problems I see with TLT is lack of exposure. If bladder cancer patients see cancer free patients ate 3, 6 and 12 months, they are more likely to enroll, more uroligist will hear about the success and refer more patients. So it helps everyone. Another issue I see if that if they have the 3 month data and do not release it, that will be a major material event they will not be disclosing, also, moat of the time with public companies, no news is bad news. If I was a patient considering certain trials and knew a company had results, but didn't want to disclose them, I would think twice about that their motive is. Waiting for some conference to get better exposure doesn't seem right when you are talking about cancer patients lives. It will also make any insider buys and sales extrmemly questionable. They will be playing with fire if they hold back material information and this company can't afford to burn themselves anymore. I hope they understand this...


G1
Bullboard Posts